

Screening for early detection of bile duct atresia through QR code

Volume 15 Issue 2 - 2024

Cinthia Bastianelli, Adriana Spiess, Analía Gallardo, Margarita Ramonett

Hospital Publico Materno infantil Salta, Argentina

Correspondence: Cinthia Bastianelli, Hospital Publico Materno infantil Salta, Argentina, Email cvbastianelli@gmail.com**Received:** February 28, 2024 | **Published:** March 21, 2024

Opinion

Bile duct atresia (BAA) is the most common cause of obstructive jaundice in the first three months of life and is responsible for 40% to 50% of all liver transplants in children worldwide. Although the etiology of AVB is unknown, it is associated with developmental anomalies, ischemic phenomena, arterial malformations, and viral infections.¹

AVB is an inflammatory, obstructive and idiopathic process of the bile ducts that evolves to biliary cirrhosis, affecting the intra- and extrahepatic bile ducts, which ends with fibrosis and obliteration of the biliary tract with the development of biliary cirrhosis, portal hypertension and liver failure, causing death within 2 to 3 years of life, if there is no surgical intervention. Early surgery, hepato-porto enteroanastomosis (Kasai surgery), before the first two months of life, offers the best chance of long-term survival of the patient with native liver.²

In the follow-up of patients with AVB after portoenteroanastomosis, more than half normalize bilirubin within six months after surgery and 5-year survival with the native liver is 30% to 60%. Approximately 20% of patients undergoing surgery survive beyond the age of 18. The level of serum bilirubin after surgery is the most important evolutionary predictor. Its normalization anticipates a favorable evolution in the long term.³

It is estimated that the worldwide prevalence of the disease ranges from 1 in 6000 to 19,000 live newborns (Taiwan: 1:6,000; USA: 1:12,000; Europe: 1:18,000; Canada 1:19,000), it occurs in all regions of the world, but it is more common in Asian countries and in women.⁴ There is a firm consensus in the pediatric literature that efforts for the early detection of biliary atresia should not be delayed, since its prognosis depends on early diagnosis and treatment; This continues to be a challenge for the pediatrician.

In cases of jaundice that last beyond two weeks of life, it is essential to determine direct bilirubin without delay and always evaluate the color of the fecal matter.⁵ The clinical presentation of AVB is usually a full-term newborn, with adequate weight, normal appearance, with progressive jaundice and acholia between 2 and 6 weeks of life. Coluria and discoloration of feces are important elements in the clinical examination. Hepatomegaly is always present, of increased consistency and sometimes accompanied by splenomegaly.

The diagnosis of AVB should be considered in an infant, one month old, jaundiced, with acholic stools and hepatomegaly.⁶

If portoenteroanastomosis is performed during the first 60 days of life, approximately 70% of patients restore bile flow, while after 90 days, less than 25% of operated patients will.

The detection of jaundiced infants with acholic or hypocolic stools using the screening method with colorimetric tables is feasible, simple, non-invasive and low cost. These represent a unique opportunity to detect neonatal cholestasis at an early age.⁷


Matsui and Dodoriki (1995), in Japan, developed colorimetric tables, achieving through them the Kasai operation before 60 days of life. Universal screening in Taiwan was established, using a similar method, increasing the sensitivity for AB detection from 72.5% to 97.1% from 2004-2005.⁸

In our country, a pilot, prospective, observational study was carried out at the Prof. A. Posadas National Hospital (1999-2002), using the fecal screening method with printed colorimetric cards (Figure 1), in all newborns born in the hospital and were treated at the first month's check-up. Of a total of 12,484 children, 4,239 (33.9%) attended the first month's visit with the colorimetric card. 18 were identified with hypo/acholic stools, of which only 4 presented cholestatic disease. The definitive diagnoses were: Alagille syndrome, luetic hepatitis, transient neonatal cholestasis and gallstones. Although no case of BA was identified, the screening test proved to be useful for detecting other causes of CN. Based on this experience, it was decided to implement screening with colorimetric cards as a routine practice in that hospital. Until now, this strategy allowed the detection of children with neonatal cholestasis born in the hospital, but monitored in peripheral centers. Quick communication with the hospital allowed the referral and performance of the Kasai. With the experience gained since 1999 to date at the Posadas Hospital we think and work hard so that this strategy can be used throughout the country.

For this reason, currently from the Children's Gastroenterology Unit of the Maternal and Child Public Hospital of Salta Argentina, this neonatal screening for early detection of AVB was developed in an innovative way using technology. A QR Code is used that is attached to the vaccination card of the RNs (Figure 2) who are born in the Hospital and the comprehensive health care card of the children of the province (Figure 3), as well as on the posters (Figure 4) with information from the investigation distributed in hospitals and health centers in the province.⁹

This code directs to a survey that contains contact information, affiliations of the mother and child, and the colorimetric table (Figure 5) of the stools. It must be completed by our patients' caregivers between 15 and 30 days of life, in order to compare the color of the stools with those in the table. If you mark the numbering from 1 to





4 in the table, which corresponds to acholic stools, it is suggested that adults consult quickly with their pediatrician and then be referred before 45 days of life to a gastroenterologist who will complete the studies if necessary.¹⁰







Detección de atresia de vías biliares

Observe las cacas de su hijo entre los 15 y 30 días de vida!

ANORMAL


1	2	3	4
			

NORMAL

5	6	7	8
			

Si el color es igual al de los cuadros 1, 2, 3 o 4 no espere y llévelo inmediatamente al pediatra!

Si la enfermedad no se detecta antes de los 2 meses de vida, la misma es grave. Escaneá el código QR a partir de los 15 días de vida de su hijo y llevalo al control con el pediatra, para ser derivado a gastroenterología infantil.





Unidad de
Gastroenterología
Pediátrica HPMI



DIRECCION MATERNO E INFANCIA
SUBSECRETARIA DE MEDICINA SOCIAL

Ministerio de Salud Pública
Gobierno de Salta

Figure 1

CERTIFICADO DE VACUNAS A NIÑOS Y ADOLESCENTES

Las vacunas son gratuitas y obligatorias. Son un derecho y una responsabilidad de todos.

Nombre y Apellido: _____

Fecha de Nacimiento: _____

DNI: _____


Domicilio: _____

Localidad: _____

Provincia: _____

Más información:
salud.gob.ar / 0-800-222-1002

Dirección de Control de Enfermedades Inmunoprevenibles



Escaneá este Código QR y responde las preguntas para la detección precoz de atresia de vías biliares

ES MUY IMPORTANTE HACERLO ENTRE LOS 15 Y 30 DÍAS DE VIDA DE TU BEBÉ!

Unidad de Gastroenterología HPMI

(1) Residentes en zona de riesgo único reducen a los diez años de la primera dosis.

(2) Dosis separadas por intervalo mínimo de 6 meses.

(3) La 1ª dosis debe administrarse antes de las cuatro semanas y seis días o tres meses y medio.

(4) La 2ª dosis debe administrarse antes de las veinticuatro semanas o los dos meses de vida.

Figure 2

CARNET DE VACUNACIÓN

Embarazadas

- ☐ Triple Bacteriana Acelular
(a partir de la semana 20 de gestación)
- ☐ Antitriplicar
- ☐ Hepatitis B (iniciar o completar esquema)

Se recomienda vacuna Covid en embarazadas y niños a partir de los 6 meses.

Recién Nacido

- ☐ BCG (única dosis)
- ☐ Hepatitis B (en las primeras 12 hs. de vida)

3 Meses

- ☐ Meningococo (primera dosis)

4 Meses

- ☐ Pentavalente (segunda dosis)
- ☐ Antipoliomielítica (segunda dosis)
- ☐ Rotavirus (segunda dosis)
- ☐ Antineumocócica -
- ☐ Prevenir I3 (segunda dosis)

5 Meses

- ☐ Meningococo (segunda dosis)

6 Meses

- ☐ Pentavalente (tercera dosis)
- ☐ Antipoliomielítica (tercera dosis)
- ☐ Antitriplicar (primera dosis)

12 Meses

- ☐ Hepatitis A (única dosis)
- ☐ Triple Viral (primera dosis)
- ☐ Antineumocócica - Prevenir (refuerzo)

15 Meses

- ☐ Varicela (primera dosis)
- ☐ Quíntuple (refuerzo)
- ☐ Meningococo (refuerzo)

18 Meses

- ☐ Fiebre Amarilla (sólo en zonas de riesgo)

Ingreso Escolar - 5 Años

- ☐ Antipoliomielítica
- ☐ Triple Bacteriana
- ☐ Triple Viral (segunda dosis)
- ☐ Varicela (refuerzo)

11 Años

- ☐ Triple Bacteriana Acelular
- ☐ VPH (Virus del Papiloma Humano dos dosis separadas por seis meses)
- ☐ Meningococo
- ☐ Fiebre Amarilla (sólo en zonas de riesgo)

Antigripal: los niños entre 6 a 24 meses deben recibir 2 dosis separadas por un mes.

IMPORTANTE

SE RECOMIENDA LA LACTANCIA MATERNA EXCLUSIVA HASTA LOS 6 MESES DE VIDA Y, DESPUÉS, HASTA LOS 2 AÑOS

A diagram illustrating the recommended duration of breastfeeding. At the top, it says "ALIMENTACIÓN COMPLEMENTARIA OPORTUNA, VARIEDAD Y COMPLETA". Below this, a staircase graphic shows the progression from exclusive breastfeeding at birth to the introduction of complementary feeding by 6 months, continuing until 11 months. The x-axis is labeled "MESES" (Months) from 1 to 11. The y-axis is labeled "LECHE MATERNA" (Breast Milk).

CONDUCTAS ESPERADAS

EDAD

DE 0 A 3 MESES	<ul style="list-style-type: none"> Acostado boca abajo, levanta la cabeza. Sonríe, sigue con la mirada a personas y objetos. Emite sonidos guturales (agu-agu). 	
DE 4 A 6 MESES	<ul style="list-style-type: none"> Se sienta con ayuda. Reconoce a la madre o persona que lo atiende. Intenta tomar objetos a mano plana. Atiende con interés el sonido. Babucea (da-da, ma-ma). 	
DE 7 A 9 MESES	<ul style="list-style-type: none"> Se sienta sin apoyo. Juega a las escondidas. Sostiene un objeto en cada mano, suelta uno para tomar otro. Emite sonidos específicos (da-da, ma-ma, ta-ta). 	
DE 10 A 12 MESES	<ul style="list-style-type: none"> Se arrastra, gatea. Da los primeros pasos con ayuda. Entiende lo que le llaman por su nombre y la orden "No". Hace juegos simples (torrillas, aplausos, imita gestos). Toma un objeto pequeño entre el pulgar y el índice. 	
DE 13 A 18 MESES	<ul style="list-style-type: none"> Camina solo, primero con inseguridad mejorando hasta correr. Maneja la cuchara y la taza, usa ambas manos. Inicio el conocimiento de las partes del cuerpo. Obedece órdenes sencillas. 	
DE 19 A 24 MESES	<ul style="list-style-type: none"> Camina y corre, salta con ayuda. Utiliza mas palabras, señala partes del cuerpo. Se pone alguna ropa, ayuda en tareas sencillas. Inicio el Control de Estiramiento. 	
DE 2 A 3 AÑOS	<ul style="list-style-type: none"> Contruye frases completas. Imita trazos con un lápiz (línea vertical). Se lava y seca las manos. Ejecuta las indicaciones que se le da "Llévate esto a mamá". 	
DE 3 A 4 AÑOS	<ul style="list-style-type: none"> Salta. Se abotona botones grandes de la ropa. Da su nombre completo. Copia cruces y círculos. Controla sus estiramiento. 	
DE 4 A 5 AÑOS	<ul style="list-style-type: none"> Salta en un sólo pie. Se viste sola. Copa el dibujo de un cuadro. Cuenta cuantos. 	

Dirección Provincial de Nutrición y Alimentación Saludable
Ministerio de Salud Pública
Gobierno de Salta

CARNET DE ATENCIÓN INTEGRAL DE SALUD DE LA NIÑA

MI NOMBRE ES:

DNI/CUIL:

FECHA DE NACIMIENTO ____ / ____ / ____ SEXO: ____

EDAD GESTACIONAL: ____ sem. PESO AL NACER: ____ kg.

TALLA AL NACER ____ cm. PERÍMETRO CEFÁLICO: ____ cm.

MI MAMÁ SE LLAMA: _____

D.N.I./CUIL: _____

MI PAPÁ SE LLAMA: _____

D.N.I./CUIL: _____

ÁREA OPERATIVA: _____

VIVO EN: _____

CALLE: _____ Nº: _____

SECTOR: _____ CASA: _____

ESTABLECIMIENTO: _____

TELÉFONO DE CONTACTO: _____

¿Sabías qué, mirando la caca de tu bebé podés detectar problemas de salud? Escanea el código QR y completa la encuesta entre los 15 y 30 días de vida de tu bebé.

Figure 3

Atención!

Pesquisa de colestasis neonatal



Importante





Si la materia fecal es de color anormal, puede ser una enfermedad grave del hígado, consulta a tu medico mas cercano.



Si tu Bebé tiene entre 15 y 30 dias de vida, escanea el código QR, completá la encuesta y compará su materia fecal con la tabla de colores.

Dra. Cinthia Bastianelli Dra. Analía Gallardo Dra. Margarita Ramonet Dra. Adriana Spies

Figure 4



Área Operativa Norte

Hospital Público Materno Infantil

SALTA

Ministerio de Salud Pública
Gobierno de Salta

Pesquisa de colestasis neonatal para detección de atresia de vías biliares

La pesquisa sirve para buscar enfermedades graves del hígado en recién nacidos como la atresia de vías biliares que necesitan TRASPLANTE DE HIGADO.

Debes realizarla entre los 15 y 30 días de vida de tu hijo para comparar el color de la materia fecal. Solo completando la encuesta podemos detectar esta enfermedad. Si la materia fecal es ANORMAL nos contactaremos con Ustedes pero DEBEN CONSULTAR inmediatamente con su pediatra o al gastroenterólogo infantil.

Esta pesquisa es de CARÁCTER OBLIGATORIO SEGUN LEY provincial N^a 8384/23.




Figure 5

Our unit controls the responses received weekly and corroborates the marked numbering. If abnormal numbering is detected, the family member is summoned through the hospital's Telemedicine to confirm or rule out acholia and evaluate the patient.¹¹ This AVB screening program has been in operation for 15 months and so far we have detected 3 patients with cholestasis, of which 1 presented AVB and another 2 presented other causes of cholestasis. We obtained more than 2725 responses (35%) from newborns in the hospital.

This project was approved by the Secretariat of Maternity and Childhood of the Ministry of Health of the province, as well as, it was approved by the Gastroenterology and Nutrition committees of SAP Branch Salta and by the Hepatology Committee at the Central level. In addition, the Neonatal Cholestasis law has just been approved in the province.¹²

Our ultimate goal is that all newborns in the province of Salta and the country can use this screening to detect AVB before 45 days of life and achieve early surgery that improves their prognosis and quality of life.¹³

Conflicts of interest

None.

Acknowledgments

None.

References

- Arguelles F, García Md. Tratado de Gastroenterología, Hepatología y Nutrición Pediátrica. Oceano (2011) Cap 3.4 Tomo II; 427–444.
- McInerney, Adam. Tratado de pediatría. 2009. Tomo II, Cap 202. pág 1739–1749.
- De Bruyne R, Van Biervliet S. Clinical practice: neonatal cholestasis. *Eur J Pediatr*. 2011;170(3):279–284.
- Fawaz R, Baumann U. Guide for evaluation of cholestasis jaundice in infants: joint recommendations of the North America Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *JPGN*. 2017;64:154–168.
- Schreiber R, Butler A. Screening for biliary atresia: it's in the cards. *Canadian Family Physician*. 2017;63(6):424–425.
- Ramonet M, Ciocca M, Alvarez F. Atresia biliar: una enfermedad grave. *Arch Argent Pediatr*. 2014;112(6):542–547.
- Woolfson JP, Schreiber RA, Butler AE, et al. Province-wide biliary atresia home screening program in british columbia: evaluation of first 2 years. *J Pediatr Gastroenterol Nutr*. 2018;66(6):845–849.
- Matsui A, Dodoriki M. Screening for biliary atresia. *Lancet*. 1995;345:1181.
- Schreiber RA, Masucci L, Kaczorowski J, et al. Home-based screening for biliary atresia using infant stool colour cards: a large-scale prospective cohort study and cost-effectiveness analysis. *J Med Screen*. 2014;21(3):126–132.
- Morinville V, Ahmed N, Ibberson C, et al. Home-based screening for biliary atresia using infant stool color cards in canada: quebec feasibility study. *J Pediatr Gastroenterol Nutr*. 2016;62(4):536–541.
- Hoshino E, Moriwaki K, Morimoto K, et al. Cost-effectiveness analysis of universal screening for biliary Atresia in Japan. *J Pediatr*. 2023;253:101–106.
- Ramonet M, Gómez S, Morise S. Detección precoz de la colestasis neonatal en las heces por el método de tamizaje con tarjetas colorimétricas. *Arch Argent Pediatr*. 2013;111(2):128–139.
- Hsiao CH, Chang MH, Chen HL, et al. Universal screening for biliary atresia using an infant stool color card in Taiwan. *Hepatology*. 2008;47(4):1233–1240.